RxNorm 1594659
Lemtrada
RxNorm Semantic Concepts
RxNorm semantic concepts for the RxCUI 1594659 unique identifier include: Lemtrada (6812461).
RxNorm Atom ID: 6812461 - Brand Name
Lemtrada
- RXCUI:
- 1594659 - RxNorm Unique Identifier for a concept (Concept ID)
- LAT:
- ENG - Language of the Term
- RXAUI:
- 6812461 - Unique identifier for the atom (RxNorm Atom ID)
- Is Prescribable?
- YES - This drug is part of the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States. The Current Prescribable subset also includes over-the-counter drugs.
- Concept Description:
- Lemtrada - Description of concept identifier
- Term Type (TTY):
- BN - Term type in source with name and description
- Term Type Name:
- Brand Name - Name of term type in source
- Term Type Description:
- A proprietary name for a family of products containing a specific active ingredient. - Description of term type in source
- Code:
- 1594659 - "Most useful" source asserted identifier. If the source vocabulary has more than one identifier, or a RxNorm-generated source entry identifier. (if the source vocabulary has none.)
- Suppress Flag:
- N
Suppressible flag. Values = N, O, Y, or E. N - not suppressible. O - Specific individual names (atoms) set as Obsolete because the name is no longer provided by the original source. Y - Suppressed by RxNorm editor. E - unquantified, non-prescribable drug with related quantified, prescribable drugs. NLM strongly recommends that users not alter editor-assigned suppressibility. - CVF:
- 4096 - Content view flag. RxNorm includes one value, '4096', to denote inclusion in the Current Prescribable Content subset. All rows with CVF='4096' can be found in the subset.
- Source:
- RXNORM - Concept source abbreviation
- Source Name:
- RxNorm Vocabulary - The official name for a source
- Source Version:
- 20AA_240401F - The source version
- Source Date:
- March 04, 2024 - RxNorm data last updated
- Source License Contact:
- RxNorm Customer Service
U.S. National Library of Medicine
8600 Rockville Pike
Bethesda
MD
United States
20894
(888) FIND-NLM
[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source license contact information - Source Content Contact:
- RxNorm Customer Service
U.S. National Library of Medicine
8600 Rockville Pike
Bethesda
MD
United States
20894
(888) FIND-NLM
[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source content contact information - Source Short Name:
- RxNorm work done by the National Library of Medicine - The short name of a source as used by the NLM Knowledge Source Server
RxNorm Atom 6812461 Attributes
Property | Value | Explanation |
---|---|---|
RXN BN CARDINALITY | single | Cardinality of RxNorm Brand Name Atom |
* This product uses publicly available data courtesy of the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Patient Education
Alemtuzumab Injection (Chronic Lymphocytic Leukemia)
Alemtuzumab injection is used to treat B-cell chronic lymphocytic leukemia (B-CLL; a slowly developing cancer in which too many of a certain type of white blood cell accumulate in the body). Alemtuzumab is in a class of medications called monoclonal antibodies. It works by activating the immune system to destroy cancer cells. Alemtuzumab is also available as an injection (Lemtrada) that is used to treat multiple sclerosis (a disease in which the nerves do not function properly; you may experience weakness, numbness, loss of muscle coordination and problems with vision, speech, and bladder control). This monograph only gives information about alemtuzumab injection (Campath) for B-CLL. If you are receiving alemtuzumab for multiple sclerosis, read the monograph entitled Alemtuzumab Injection (Multiple Sclerosis).
[Learn More]
Alemtuzumab Injection (Multiple Sclerosis)
Alemtuzumab injection is used to treat adults with various forms of multiple sclerosis (MS; a disease in which the nerves do not function properly and people may experience weakness, numbness, loss of muscle coordination, and problems with vision, speech, and bladder control) who have not improved with at least two or more MS medications including: relapsing-remitting forms (course of disease where symptoms flare up from time to time) or secondary progressive forms (course of disease where relapses occur more often). Alemtuzumab is in a class of medications called monoclonal antibodies. It works by decreasing the action of immune cells that may cause nerve damage. Alemtuzumab is also available as an injection (Campath) that is used to treat chronic lymphocytic leukemia (a slowly developing cancer in which too many of a certain type of white blood cell accumulates in the body). This monograph only gives information about alemtuzumab injection (Lemtrada) for multiple sclerosis. If you are receiving alemtuzumab for chronic lymphocytic leukemia, read the monograph entitled Alemtuzumab Injection (Chronic Lymphocytic Leukemia).
[Learn More]
* Please review the disclaimer below.